Clinical trials: First Line Treatment
Gastric Cancer
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to evaluate progression-free survival in participants with gastric or gastroesophageal junction cancer who have had disease progression following first-line therapy who undergo treatment with…
- Trial name
- NCT01983878
- Testing
- Ramucirumab
- Where
- 11 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00602043
- Testing
- F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
The purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not previously received any treatment for…
- Trial name
- EGFR (NCT02186301)
- Testing
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Where
- 74 sites in United States, Germany and 5 more
- Volunteers
- 100 people
- Sponsor
- Clovis Oncology, Inc.
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
HIV Infections
Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
For treatment of human immunodeficiency virus type 1(HIV-1), publicly funded programmes tend to follow World Health Organization (WHO) guidelines to use a non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two…
- Trial name
- NCT02227238
- Testing
- DTG, LPV/RTV, Two NRTIs
- Where
- 59 sites in Argentina, Brazil and 11 more
- Volunteers
- 627 people
- Sponsor
- ViiV Healthcare
Carcinoma of the Head and Neck
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study is conducted in Japanese newly diagnosed locally advanced SCCHN patients in order to assess tolerability and feasibility of Cetuximab plus concomitant boost radiotherapy (RT) regimen (the study treatment) and its…
- Trial name
- NCT00865098
- Testing
- Cetuximab
- Where
- 4 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diffuse Large B-Cell Lymphoma
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.
- Trial name
- NCT00355199
- Testing
- Rituximab-HDS, Rituximab-CHOP
- Where
- 16 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Gruppo Italiano Terapie Innovative nei Linfomi
Carcinoma, Nonsquamous Non-small-cell Lung
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976323
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with…
- Trial name
- NCT05224141
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Etoposide, Cisplatin
- Where
- 140 sites in United States, Argentina and 23 more
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma…
- Trial name
- NCT03433703
- Testing
- Lenvatinib
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
The study will compare the efficacy and safety of treatment with pembrolizumab (MK-3475) versus paclitaxel in Asian, programmed death-ligand 1 (PD-L1) positive participants with advanced gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT03019588
- Testing
- Pembrolizumab, Paclitaxel
- Where
- 36 sites in China, Malaysia and 2 more
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT01253642
- Testing
- Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus…
- Trial name
- NCT01120184
- Testing
- docetaxel, paclitaxel, pertuzumab
- Where
- 257 sites in United States, Argentina and 36 more
- Volunteers
- 1,095 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as…
- Trial name
- APEC (NCT00778830)
- Testing
- Cetuximab, FOLFIRI, FOLFOX
- Where
- Singapore
- Volunteers
- 289 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine…
- Trial name
- NCT00838578
- Testing
- KRN330, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
This single arm study will assess the efficacy and safety of Avastin in combination with Herceptin and Xeloda as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancer.
- Trial name
- NCT00811135
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 35 sites in Denmark, France and 4 more
- Volunteers
- 88 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
- Trial name
- NCT02533401
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 9 sites in Argentina, Venezuela
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche